You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,322,066


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,322,066
Title:Predictors for cancer treatment
Abstract: The present invention provides methods of predicting a response to a cancer treatment by determining CD68 level or PSMB1 (P11A) polymorphism in a biological sample and the presence or quantity of a second biomarker in the patient. The invention also provides kits and methods for treating cancer.
Inventor(s): Ricci; Deborah (Ringoes, NJ), Li; Weimin (Radnor, PA), Henitz; Erin DeVay (Flemington, NJ)
Assignee: Janssen Pharmaceutica NV (Beerse, BE)
Application Number:13/569,517
Patent Claims:1. A method for predicting response to a cancer treatment comprising bortezomib and rituximab in a non-Hodgkin's lymphoma cancer patient, comprising: detecting the presence of a first predictor in a biological sample from said non-Hodgkin's lymphoma cancer patient, wherein said first predictor is low CD68; detecting the presence of a second predictor in said non-Hodgkin's lymphoma cancer patient, wherein said second predictor is a PSMB1 (P11A) polymorphism comprising a C/G heterozygote; wherein the presence of a biomarker pair comprising the low CD68 and the PSMB1 (P11A) polymorphism is correlated with at least one positive outcome; and selecting the non-Hodgkin's lymphoma cancer patients that have an increased chance for a favorable outcome to the cancer treatment comprising bortezomib and rituximab based on the presence of the biomarker pair comprising the first and second predictor; and treating the selected non-Hodgkin's lymphoma cancer patients with the cancer treatment comprising bortezomib and rituximab.

2. The method of claim 1, wherein low CD68 is 50% or less CD68-positive cells, as determined by immunohistochemistry.

3. The method of claim 1, wherein the non-Hodgkin lymphoma is follicular B-cell non-Hodgkin lymphoma.

Details for Patent 9,322,066

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2031-08-11
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2031-08-11
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2031-08-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.